Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Advancing Approaches to Atopic Dermatitis Management : Episode 5

Opinion

Video

March 6, 2025

Switching Biologic Therapies in a 32-Year-Old Woman With Severe Atopic Dermatitis

Author(s):

The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Recognizing Atopic Dermatitis Heterogeneity and Tailoring Treatment

EP: 2.Navigating Pediatric Treatment Options for a 10-Year-Old Girl

EP: 3.Discussing Efficacy and Safety of Dupilumab With Patients and Caregivers

EP: 4.Tackling Topical Treatments for a 24-Year-Old Man With Mild Atopic Dermatitis

Now Viewing

EP: 5.Switching Biologic Therapies in a 32-Year-Old Woman With Severe Atopic Dermatitis

EP: 6.Oral Treatment Options for a 36-Year-Old Man With Prior Systemic Corticosteroid Use

EP: 7.Recapping the Evolving Treatment Landscape for Atopic Dermatitis

EP: 8.Using Real-World AD Cases to Pick the Right Therapy for Each Patient

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Videos

Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management

Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice

Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments

Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines

The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies

What Lies Ahead for GPP Diagnosis and Management

Case 3: High-Risk Patient with GPP Treatment Approach

Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care

Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?

Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making